USDA Grand Forks Human Nutrition Research Center
USDA Grand Forks Human Nutrition Research Center sponsors 57 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 47 completed. The most-studied condition in this pipeline is Overweight, with 4 trials.
Trial Pipeline
57 total, page 2 of 2
Magnesium Nutrition and Sleep Behavior in Older Adults
NCT00833092
Iron Bioavailability From MyPyramid Menus
NCT00754234
Predicting Dietary Selenium Needs to Achieve Target Blood Selenium Levels
NCT00803699
Effects of Calcium and Phytate on Zinc Absorption
NCT00754390
Dietary Fat, Eicosanoids and Breast Cancer Risk
NCT01824498
Meat Protein and Calcium: Do They Interact Synergistically or Antagonistically?
NCT00700804
Measurements of Body Iron Excretion of Healthy Adults
NCT00755105
Therapeutic Areas
What the Pipeline for USDA Grand Forks Human Nutrition Research Center Shows
According to the ClinicalTrials.gov registry, USDA Grand Forks Human Nutrition Research Center is linked to 57 US clinical trials across every stage of research activity. Of those, 2 studies are currently recruiting, about 4% of the sponsor's indexed portfolio, and 47 are already marked complete, representing roughly 82% of the total.
The phase mix for USDA Grand Forks Human Nutrition Research Center reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for USDA Grand Forks Human Nutrition Research Center is Overweight with 4 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.